Viewing Study NCT03261206


Ignite Creation Date: 2025-12-26 @ 5:21 PM
Ignite Modification Date: 2026-03-01 @ 4:12 PM
Study NCT ID: NCT03261206
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-05-20
First Post: 2017-08-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Stopping Aminosalicylate Therapy in Inactive Crohn's Disease
Sponsor: Alimentiv Inc.
Organization:

Study Overview

Official Title: Stopping Aminosalicylate Therapy in Inactive Crohn's Disease (STATIC) Study: A Randomized, Open-label, Non-inferiority Trial
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2025-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: STATIC
Brief Summary: The purpose of this study is to assess whether withdrawal of aminosalicylate (5-ASA) is non-inferior to continuation of 5-ASA therapy in Crohn's disease (CD) subjects in remission.
Detailed Description: Aminosalicylate (5-ASA) agents have proven effective for inducing and maintaining remission in mild to moderate ulcerative colitis (UC) and thus are commonly used as first-line agents for patients with Crohn's disease (CD) in remission. However, there is uncertainty regarding their effectiveness for CD.

In this open-label, randomized study, participants with CD in remission will be allocated to either continue their 5-ASA therapy or withdraw their 5-ASA. The purpose is to investigate if withdrawal of 5-ASA therapy is not unacceptably less effective than continuing on 5-ASA in maintaining CD remission over a 24 month period.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: